Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis

NCT07235904 | Recruiting Phase 4

• 2 other identifiers: MIRACLE2025-522585-72-00
• Study Type: interventional
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

The MIRACLE trial is for patients who have been newly diagnosed with moderate to severe ulcerative colitis in the last 12 months and who have not responded adequately to treatment with mesalazine and prednisolone alone. The standard drug therapy for ulcerative colitis begins with mesalazine (+cortisone) and, if the response is insufficient, continues with azathioprine (+cortisone). Only in the next step are biologics (biotechnologically produced protein substances such as antibodies) such as mirikizumab used as needed. Recent studies have now shown that earlier treatment with mirikizumab without prior treatment with azathioprine may be more effective in the long term, and there are indications that this may result in fewer side effects. This study aims to investigate whether direct, early treatment with mirikizumab is more effective than the usual initiation of standard therapy with azathioprine, whereby these patients can then switch to mirikizumab at predetermined times during the course of the study from week 24 onwards if they have a defined disease activity despite the previous azathioprine treatment. The study consists of an initial treatment period of 12 weeks (induction therapy) and a maintenance therapy period of 40 weeks. Patients in the mirikizumab arm receive 12 doses of mirikizumab. This includes initially 300 mg intravenously every 4 weeks at the trial site, followed by 200 mg subcutaneously via two subcutaneous injections of 100 mg each, administered independently at home. In the azathioprine arm patients receive daily administration of azathioprine tablets in combination with a steroid. Assignment to one of the two treatment options is randomised with equal probability for each of the treatment options.

Conditions

Ulcerative Colitis (UC)

Outcome Measures

Primary Outcomes (1)

• comprehensive disease control

  The proportion of patients achieving comprehensive disease control at Week 52, defined as: Steroid-free clinical remission (modified Mayo score remission \[ES ≤1, SF ≤1, RB=0\] and no glucocorticoid use for at least 12 weeks prior to week 52) achieved without surgery, and Biochemical remission (CRP \<0.5 mg/dl and Fcal \<250 μg/g stool), and Endoscopic improvement (eMayo=0-1), and Histologic remission (RHI ≤3, with subscores of 0 for lamina propria neutrophils and of 0 for neutrophils in epithelium), and Normalization of IBD-related QoL (sIBDQ ≥60 points).

  Week 52

Study Arms (2)

Mirikizumab

EXPERIMENTAL

Drug: Mirikizumab

Azathioprine

ACTIVE COMPARATOR

Drug: Azathioprine (AZA)

Interventions

Mirikizumab DRUG

Patients in the mirikizumab arm will receive an initial 300 mg dose every 4 weeks intravenously for three doses during the 12-week induction period.After completing induction, patients will switch to maintenance therapy with 200 mg mirikizumab subcutaneously.

Mirikizumab

Azathioprine (AZA) DRUG

Patients in the azathioprine arm will receive oral azathioprine at a dose of 2.0-2.5 mg/kg body weight daily in combination with an initial daily dose of 40-60 mg glucocorticoids, which may be tapered as clinically appropriate.

Azathioprine

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have given written informed consent prior to any study-specific procedures being completed.
• Are willing and able to complete the scheduled study assessments, including endoscopy and daily diary entry.
• Are willing to comply with contraception requirements (as specified in section 7.7)
• Age between 18 and 75 years.
• Naïve to azathioprine and its metabolite 6-MP
• Naïve to advanced therapies.
• Early disease (duration \< 12 months since first diagnosis).
• Patients with active ulcerative colitis (UC) for whom a previous therapy with 5-aminosalicylic acid (5-ASA) or steroids have not worked well enough, have stopped working, or have caused unacceptable side effects.
• The steroid oral therapy must have been stable for at least two weeks before baseline and may consist of prednisone ≤20 mg/day (or equivalent) per os.
• The oral 5-ASA therapy must have been ongoing for at least 8 weeks and dose must be stable for at least 2 weeks before baseline.
• Modified Mayo score (mMS) 5-9.
• Endoscopic Mayo (eMayo) score ≥2 (local).
• Robarts Histopathology Index (RHI) \>4 (central)
• Elevated CRP (above the upper limit of normal) or Fcal (above 250 ug/g stool).
• Disease localization involving at least the rectum and sigmoid colon (\>15 cm).

You may not qualify if:

• Fulminant ulcerative colitis patients who do not respond to steroid treatment or requiring \>20 mg of prednisolone (or equivalent) at baseline and/or fulfilling the criteria for severe UC (requirement of hospitalization) .
• Patients with complex UC who have required cyclosporine and tacrolimus for previous treatment
• Treatment with MTX within 8 weeks before baseline
• Rectal 5-ASA or rectal steroids treatment within 2 weeks prior to baseline
• History of malignancy, except for non-melanoma skin cancer.
• Known thiopurine methyltransferase deficiency.
• Known hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
• Diagnosis of Crohn's disease.
• Have been diagnosed with clinically important infection including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB).
• Have detectable hepatitis B virus (HBV) DNA. or hepatitis C virus (HCV) RNA
• Have been diagnosed with latent TB and are not willing to comply with completing TB treatment as appropriate.
• Intend to receive a Bacillus Calmette-Guerin (BCG) vaccination or live attenuated vaccine(s) during the study.
• Have been diagnosed with systemic mycoses and parasitosis
• Have an unstable or uncontrolled illness, including, but not limited to, cerebrocardiovascular, respiratory, gastrointestinal (excluding UC), hepatic, renal, endocrine, hematologic or neurological disorders or malignancy that would potentially affect patient safety within the study or confound efficacy assessment.
• Have a known systemic hypersensitivity to any component of this investigational product or has experienced an acute systemic hypersensitivity event with previous study drug administration, that precludes mirikizumab therapy.

Sponsors & Collaborators

• University Hospital Schleswig-Holstein: lead

Study Sites (1)

University Hospital Schleswig-Holstein

Kiel, Germany

RECRUITING

MeSH Terms

Conditions

Colitis, Ulcerative

Interventions

mirikizumab; Azathioprine

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Intervention Hierarchy (Ancestors)

Thionucleosides; Sulfur Compounds; Organic Chemicals; Mercaptopurine; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 30, 2025
• First Posted: November 19, 2025
• Study Start: December 5, 2025
• Primary Completion (Estimated): March 1, 2028
• Study Completion (Estimated): October 1, 2028
• Last Updated: December 16, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)